Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 3Terminated 2Recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Fatigue 6Brain Neoplasms 3Neoplasms 2Depression 2Central Nervous System Neoplasms 2Breast Neoplasms 2Asthenia 2Sleep Wake Disorders 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive 1Meningioma 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Ependymoma 1Cognitive Dysfunction 1Astrocytoma 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Methylphenidate × Clear all
NCT01164956 2019-04-26

Methylphenidate for Cancer-Related Fatigue

Dana-Farber Cancer Institute

Phase 1 Terminated
3 enrolled 7 charts

Fatigue, Neoplasms

NCT00273741 2009-12-07

Ritaline

University Hospital, Grenoble

Phase 3 Terminated
39 enrolled

Asthenia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡